Represents growth of 32% at the midpoint compared to expected 2024 revenue.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026
- Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
- Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
- Verve Therapeutics announces anticipated 2025 milestones
- Potential acquisition of Scorpion positive for Relay, says Barclays